文章基本信息

标题：Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
本地全文：下载
作者：Marc Evans ; Anja Schweizer ; James E Foley 等
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2016
卷号：12
页码：337-340
DOI：10.2147/VHRM.S112148
语种：English
出版社：Dove Medical Press Ltd
摘要：Introduction: We have previously shown modest weight loss with vildagliptin treatment. Since body weight balance is associated with changes in blood pressure (BP) and fasting lipids, we have assessed these parameters following vildagliptin treatment. Methods: Data were pooled from all double-blind, randomized, controlled, vildagliptin monotherapy trials on previously drug-naïve patients with type 2 diabetes mellitus who received vildagliptin 50 mg once daily (qd) or twice daily (bid; n=2,108) and wherein BP and fasting lipid data were obtained. Results: Data from patients receiving vildagliptin 50 mg qd or bid showed reductions from baseline to week 24 in systolic BP (from 132.5±0.32 to 129.8±0.34 mmHg; P <0.0001), diastolic BP (from 81.2±0.18 to 79.6±0.19 mmHg; P <0.0001), fasting triglycerides (from 2.00±0.02 to 1.80±0.02 mmol/L; P <0.0001), very low density lipoprotein cholesterol (from 0.90±0.01 to 0.83±0.01 mmol/L; P <0.0001), and low density lipoprotein cholesterol (from 3.17±0.02 to 3.04±0.02 mmol/L; P <0.0001), whereas high density lipoprotein cholesterol increased (from 1.19±0.01 to 1.22±0.01 mmol/L; P <0.001). Weight decreased by 0.48±0.08 kg ( P <0.001). Conclusion: This large pooled analysis demonstrated that vildagliptin shows a significant reduction in BP and a favorable fasting lipid profile that are associated with modest weight loss.
关键词：TG; HDL; LDL; body weight DPP-4 inhibitor; GLP-1